secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxart, Inc. (VXRT)
CIK:        0000072444
Form:       8-K
Filed at:   2026-07-07T12:00:09+00:00
Accession:  0001437749-26-022876
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxart reports positive 12-month safety data from Phase 2b sentinel cohort of oral COVID-19 vaccine
--------------------------------------------------------------------------------

- No vaccine-related SAEs or sustained Grade 3+ AEs in either arm (201 oral pill, 199 mRNA).
- Most common AEs for oral pill: malaise/fatigue (20.9%), headache (18.9%), anorexia (10.0%).
- Sentinel cohort not powered for efficacy; 33 symptomatic COVID cases in oral arm vs 30 in mRNA arm.
- Complete study data (~5,000 main cohort participants) anticipated in 2027.
- Project NextGen/BARDA award valued at up to $344.8 million supports the trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/72444/000143774926022876/0001437749-26-022876-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/72444/000143774926022876/vxrt20260706_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-022876

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer